Showing 1641-1650 of 2192 results for "".
- Drawing the Line Between NMO & MShttps://practicalneurology.com/diseases-diagnoses/ms-immune-disorders/pn1207-nmo-feature-pdf/31083/Neuromyelitis Optica (NMO): Distinct Clinical Features and Diagnostic ChallengesNeuromyelitis optica (NMO) is a severe, relapsing inflammatory demyelinating disease of the central nervous system (CNS), primarily leading to significant vision loss and impaired mobility. Unlike multiple sclerosis (MS)
- Dementia Insightshttps://practicalneurology.com/diseases-diagnoses/alzheimer-disease-dementias/pn1207-dementiainsight-pdf/31076/Curcumin and Its Potential in Alzheimer's Disease ManagementAlzheimer’s disease (AD) remains a formidable challenge in neurology, prompting researchers to explore novel therapeutic avenues. One promising candidate is curcumin, a bioactive compound found in turmeric, a staple spice in South Asian cui
- Medicare: Take the 2008 Model for a Test Drivehttps://practicalneurology.com/columns/practice-management/medicare-take-the-2008-model-for-a-test-drive/31091/Medicare Payment Revisions and CMS Updates Impacting Neurological Practices in 2008In the November 2007 issue of *Practical Neurology*, Craig T. Williams outlines significant changes introduced by the Centers for Medicare & Medicaid Services (CMS) that are set to affect neurological practices in
- Dementia Insightshttps://practicalneurology.com/diseases-diagnoses/alzheimer-disease-dementias/pn1007-dementia-pdf/31106/Caffeine, the most widely consumed psychoactive substance globally, continues to be a focal point in neurological research, particularly regarding its potential impact on cognitive decline and Alzheimer’s disease (AD). Recent studies presented in Practical Neurology highlight both promising and inco
- Dementia Insightshttps://practicalneurology.com/diseases-diagnoses/alzheimer-disease-dementias/pn0807-dementia-pdf/31134/Recent advancements in Alzheimer’s disease (AD) research are prompting a reevaluation of the traditional amyloid-beta (Aβ) hypothesis. Historically, the focus has been on Aβ42 as the primary pathogenic species driving AD, with Aβ40 considered less harmful. However, emerging studies suggest a more nu
- News Briefshttps://practicalneurology.com/columns/practice-management/news-briefs/31165/Highlights from the APA Annual Meeting and Recent Neurological AdvancesThe 160th American Psychiatric Association (APA) Annual Meeting in San Diego featured significant discussions and presentations relevant to neurology and psychiatric medicine. Despite protests from over 300 demonstrators, includi
- Dementia Insightshttps://practicalneurology.com/diseases-diagnoses/alzheimer-disease-dementias/pn0607-demetia-insight-pdf/31160/In the June 2007 issue of *Practical Neurology*, Dr. David S. Geldmacher explores the challenges neurologists face with the outdated ICD-9-CM (International Classification of Disease, 9th Revision-Clinical Modification) coding system, particularly in diagnosing and managing dementia. Drawing an anal
- How to Give an Award-Winning Performancehttps://practicalneurology.com/columns/practice-management/how-to-give-an-award-winning-performance/31183/Medicare’s Physician Quality Reporting Initiative (PQRI) and Its Impact on Neurology PracticesAs the healthcare landscape increasingly embraces the pay-for-performance (P4P) reimbursement model, Medicare’s Physician Quality Reporting Initiative (PQRI) emerges as a pivotal program for neurologists se
- Dementia Insightshttps://practicalneurology.com/diseases-diagnoses/alzheimer-disease-dementias/pn0407-dementia-pdf/31186/As spring and summer travel seasons approach, attention often focuses on fuel prices and their impact on travel patterns. Analogously, the brain operates under a supply-and-demand framework for energy, where glucose and oxygen serve as essential “fuels.” When the brain’s energy demand surpasses supp
- Juggling the Options for Secondary Stroke Preventionhttps://practicalneurology.com/diseases-diagnoses/stroke/pn0307-secondary-stroke-pdf/31205/In the March 2007 issue of *Practical Neurology*, Dr. Stanley N. Cohen addresses the evolving landscape of secondary stroke prevention, highlighting the need for updated, evidence-based strategies amidst changing treatment paradigms. He emphasizes that while acute stroke interventions like intraveno